Estimations of generic drug entry in Brazil using count ... - EPGE/FGV

More documents

Recommendations

Info

References[1] Bae, J.P. (1997). "Drug Patent Expirations and the Speed of Generic Entry", HealthServices Research, vol. 32, 87–101.[2] Berry, S.T. (1992). "Estimation of a Model of Entry in the Airline Industry". Econometrica,Vol. 60, pp. 889-917.[3] Cameron, A.C. & Trivedi, P.K. (1998). Regression Analysis of count data. Cambridge,Cambridge U.P.[4] Chaves, G.C. & Reis, R. (2007). "Challenges for the universal access to medicines inBrazil –brief comments from civil society". International Conference on CompulsoryLicensing: Innovation and Access for All", 21-23 November 2007, Bangkok, Thailand.[5] Danzon and Chao (2000) –"Does Regulation Drive out Competion in Pharmaceuticalmarkets?". Journal of Laws & Economics, vol 43, pp.311-357.[6] European Commission (2008). Pharmaceutical Sector Inquiry – Preliminary Report/FactSheet –"Originator-Generic competition".[7] Federal Trade Commision (2002). Generic Drug Entry Prior to Patent Expiration:an FTC Study. Washington (DC).[8] Hausman, J.; Hall, B.H. & Griliches, Z. (1984). "Econometric Models for Count Datawith an application to the Patents-R& D Relationship". Econometrica, Vol. 52, No.4, pp. 909-938.[9] Homedes, N.; Linares, R.L. & Ugalde, A. (2005). Generic Drug Policies in LatinAmerica. Health, Nutrition and Population (HNP) Discussion Paper. Washington(DC): World Bank.[10] Hudson, J. (2000). “Generic take-up in the pharmaceutical market following patentexpiry: a multi-country study”. International Review of Law and Economics, vol. 20,pp. 205-221.[11] Iizuka (2008) "Generic Entry in a Regulated Pharmaceutical Market". AoyamaGakuin University. Mimeo.24
[12] Fiuza, E.P.S. & Lisboa, M.B. (2003) "Credence Goods and Market Power: An EconometricStudy of the Brazilian Pharmaceutical Industry”. Estudos Econômicos, vol.33, no. 4, pp. 601-638.[13] Frank, R. G. & Salkever, D. S. (1997). "Generic Entry and the Pricing of Pharmaceuticals".Journal of Economics & Management Strategy, Volume 6, Number 1, pp.75–90.[14] Kyle, M.K. (2003) –"Pharmaceutical Price Controls and Entry Strategies". Reviewof Economics and Statistics, vol. 89, no.1, pp.88-99.[15] Kyle, M.K. (2006) – "The role of …rm characteristics in pharmaceutical productlaunches". Rand Journal of Economics, vol. 37, no.3, pp.602-618.[16] Lanjouw, J.O. (2005) – "Patents, Price Controls and Acess to New Drugs: HowPolicy a¤ects Global Market entry". NBER Working Paper No. 11321.[17] Lambert, D. (1992), "Zero-In‡ated Poisson Regression with an Application to Defectsin Manufacturing," Technometrics, 34, 1-14.[18] Lopes, J.A.(2009). Estudo sobre a reação de preço dos medicamentos líderes de mercadoà introdução de concorrentes genéricos e similares. São Paulo: EESP/FGV.Unpublished Master’s Dissertation.[19] G.S. (1993). Limited-Dependent and Qualitative Variables in Econometrics. Cambridge(UK): Cambridge U.P.[20] Moreno-Torres, Junoy and Arqué (2007) –"Generic entry into a regulated pharmaceuticalmarket". Mimeo.[21] Nishijima M, Biasoto Jr G. (2003). Os preços dos medicamentos de referência apósa entrada dos medicamentos genéricos no mercado brasileiro. Downloadable fromhttp://www.anpec.org.br/encontro2003/artigos/D29.pdf[22] Rei¤en, D. &M.E. Ward (2005) “Generic Drug Industry Dynamics”. Review of Economicsand Statistics, Vol. 87, no. 1, pp. 37-49.25
Page 1 and 2: Estimations of generic drug entry i
Page 3 and 4: percent below 1997 level, but twent
Page 5 and 6: doctors had reason to concern that
Page 7 and 8: companies tried to switch patients
Page 9 and 10: Scott-Morton [24] used individual d
Page 11 and 12: of entries, but the longer the excl
Page 13 and 14: model families. We then discuss the
Page 15 and 16: such that i follows a Gamma distri
Page 17 and 18: Pr [y i = j] = Pr ( j 1 < yi j )
Page 19 and 20: drugs where generic entry occurred
Page 21 and 22: Ordered multinomial models display
Page 23: 3. the lagged HHI market concentrat
Page 27 and 28: TABLE 1Generic Drug Market Share in
Page 29 and 30: FIGURE 2Distribution of Accumulated
Page 31 and 32: TABLE 5 (Continued)POISSON NB2 NB1
Page 33 and 34: TABLE 7Marginal Effects of Ordered
Page 35 and 36: TABLE 8-BPRM: Predicted and actual
Page 37 and 38: FIGURE 3Deviations in Observed vs.
Page 39: FIGURE 5Sources of zeros in the ZIN

Estimations of generic drug entry in Brazil using count ... - EPGE/FGV

Create successful ePaper yourself

Delete template?

Save as template?